doi: 10.1161/01.CIR.0000019621.18368.B7
(Circulation. 2002;106:631.)
© 2002 American Heart Association, Inc.
Current Perspective |
Defining Gene Transfer Before Expecting Gene Therapy
Putting the Horse Before the Cart
From the Division of Cardiovascular Disease and Internal Medicine (B.J.G.), Department of Biochemistry and Molecular Biology, Molecular Medicine Program, Mayo Clinic and Foundation, Rochester, Minn (S.P., R.D.S.); and Cardiac Unit and Center for Transgene Technology and Gene Therapy, University of Leuven and Flanders Interuniversity Institute for Biotechnology, Leuven, Belgium (S.P.J.).
Correspondence to Robert D. Simari, MD, Mayo Clinic and Foundation, 200 First St SW, Rochester, MN 55905. E-mail simari.robert@mayo.edu
Key Words: cardiovascular diseases • gene therapy • pharmacokinetics
An extract of the first 250 words of the full text is provided, because this article has no abstract. |
 |
Introduction |
|---|
By all means keep your enthusiasm, but let verification be its constant companion.— Louis Pasteur, 1822 to 1895.
The remarkable advances in our understanding of the molecular and biochemical bases for disease during the past decade, in conjunction with the "genomic revolution," have generated understandable enthusiasm for the development of genetic therapies. Whereas the initial hope was that gene therapy would aid in the treatment of patients with primary genetic disorders, applications have now been expanded to populations with diseases in which acquired environmental and other factors play a major pathogenic role. Research into gene transfer techniques as potential therapeutic strategies for cardiovascular disease began in the early 1980s and has been translated into phase I and, more recently, phase II and III clinical trials. Currently, 46 of 509 ongoing clinical gene transfer trials are investigating cardiovascular diseases.1 The majority of gene therapy trials and studies in cardiovascular disease are aimed at testing the safety and efficacy of therapeutic angiogenesis, and to a lesser extent, examining restenosis after vascular intervention.
At this juncture, at a time of justifiable excitement and intense interest in the role of gene therapy in cardiovascular disease, it is perhaps opportune to critically review what we have learned and to discuss what directions should be taken in the near future. Gene transfer is, after all, a system of drug delivery that uses complex and potentially toxic biochemicals. Nonetheless, the emphasis of current clinical trials has been on developing individual gene transfer "products" as therapeutic agents,
This article has been cited by other articles:
 |
|
 |
|
  B. J. Gersh, R. D. Simari, A. Behfar, C. M. Terzic, and A. Terzic Cardiac Cell Repair Therapy: A Clinical Perspective Mayo Clin. Proc., October 1, 2009; 84(10): 876 - 892. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Huang, Z. Chen, S. Hu, F. Jia, Z. Li, G. Hoyt, R. C. Robbins, M. A. Kay, and J. C. Wu Novel Minicircle Vector for Gene Therapy in Murine Myocardial Infarction Circulation, September 15, 2009; 120(11_suppl_1): S230 - S237. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Huang, D. A. Chan, F. Jia, X. Xie, Z. Li, G. Hoyt, R. C. Robbins, X. Chen, A. J. Giaccia, and J. C. Wu Short Hairpin RNA Interference Therapy for Ischemic Heart Disease Circulation, September 30, 2008; 118(14_suppl_1): S226 - S233. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. P.F. Gade, J. A. Koutcher, W. M. Spees, B. J. Beattie, V. Ponomarev, M. Doubrovin, I. M. Buchanan, T. Beresten, K. L. Zakian, H. C. Le, et al. Imaging Transgene Activity In vivo Cancer Res., April 15, 2008; 68(8): 2878 - 2884. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Wu, F. M. Bengel, and S. S. Gambhir Cardiovascular Molecular Imaging Radiology, August 1, 2007; 244(2): 337 - 355. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Ollinger, M. Bilban, A. Erat, A. Froio, J. McDaid, S. Tyagi, E. Csizmadia, A. V. Graca-Souza, A. Liloia, M. P. Soares, et al. Bilirubin: A Natural Inhibitor of Vascular Smooth Muscle Cell Proliferation Circulation, August 16, 2005; 112(7): 1030 - 1039. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Watanabe and D. D. Heistad Targeting cerebral arteries for gene therapy Exp Physiol, May 1, 2005; 90(3): 327 - 331. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. Wu, I. Y. Chen, Y. Wang, J. R. Tseng, A. Chhabra, M. Salek, J.-J. Min, M. C. Fishbein, R. Crystal, and S. S. Gambhir Molecular Imaging of the Kinetics of Vascular Endothelial Growth Factor Gene Expression in Ischemic Myocardium Circulation, August 10, 2004; 110(6): 685 - 691. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Y. Chen, J. C. Wu, J.-J. Min, G. Sundaresan, X. Lewis, Q. Liang, H. R. Herschman, and S. S. Gambhir Micro-Positron Emission Tomography Imaging of Cardiac Gene Expression in Rats Using Bicistronic Adenoviral Vector-Mediated Gene Delivery Circulation, March 23, 2004; 109(11): 1415 - 1420. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Ribourtout and J. Raymond Gene Therapy and Endovascular Treatment of Intracranial Aneurysms Stroke, March 1, 2004; 35(3): 786 - 793. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Berger Ranolazine and Other Antianginal Therapies in the Era of the Drug-Eluting Stent JAMA, January 21, 2004; 291(3): 365 - 367. [Full Text] [PDF]
|
|
|
|
 |
|
 T. H. Kim, K. A. Skelding, E. G. Nabel, and R. D. Simari What can cardiovascular gene transfer learn from genomics: and vice versa? Physiol Genomics, December 3, 2002; 11(3): 179 - 182. [Abstract] [Full Text] [PDF]
|
|